ERBB2 and neoplasm: Collectively, these results propose accurate measurement of ‘true’ HER2 expression is crucial in anticipating pCR rates within this disease, while advocating for future directions to be centred around the augmentation of Trastuzumab with novel therapeutic agents, such as HIF-2a inhibitors, in efforts to increase tumour sensitivity and pCR frequencies.